US Supreme Court Review Threatens Mail‑Order Access to Abortion Pill mifepristone

The 5th U.S. Circuit Court of Appeals reinstated the FDA’s pre‑2021 requirement that mifepristone be dispensed only after an in‑person consultation, effectively ending nationwide mail‑order and pharmacy distribution of the abortion pill. Danco Laboratories, the drug’s manufacturer, filed an emergency petition with the Supreme Court seeking a stay of the ruling, arguing that the decision would cause immediate confusion for providers, patients and pharmacies.

If the Supreme Court denies the stay, patients in many states—particularly those in rural or restrictive jurisdictions—could lose the ability to obtain medication abortions remotely, forcing travel to clinics. Clinical experts note that the mifepristone‑misoprostol regimen remains safe and 95‑98% effective when used within the first 10‑11 weeks of pregnancy, and that the legal dispute does not affect the drugs’ medical safety.

The case highlights a broader clash between anti‑abortion groups, which praise the in‑person requirement as a safety measure, and the pharmaceutical company, which warns of market disruption and reduced access for patients. The outcome may shape FDA distribution policies and abortion access ahead of upcoming elections.